Deutsche Bank AG Purchases 35,733 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Deutsche Bank AG boosted its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 37.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 131,546 shares of the company’s stock after purchasing an additional 35,733 shares during the quarter. Deutsche Bank AG owned about 0.09% of MiMedx Group worth $1,265,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of MiMedx Group by 79.9% during the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock worth $802,000 after buying an additional 37,031 shares in the last quarter. Savant Capital LLC purchased a new stake in MiMedx Group in the fourth quarter worth about $100,000. Van ECK Associates Corp bought a new position in MiMedx Group during the 4th quarter worth about $40,000. Palumbo Wealth Management LLC bought a new position in MiMedx Group during the 4th quarter worth about $171,000. Finally, Principal Financial Group Inc. increased its position in MiMedx Group by 8.5% during the 4th quarter. Principal Financial Group Inc. now owns 60,226 shares of the company’s stock valued at $579,000 after purchasing an additional 4,731 shares during the period. 79.15% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other MiMedx Group news, CEO Joseph H. Capper acquired 200,000 shares of the firm’s stock in a transaction dated Friday, May 2nd. The stock was purchased at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at $3,859,237.20. The trade was a 14.13% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. 1.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wall Street Zen cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Price Performance

Shares of MDXG stock opened at $6.63 on Monday. The stock’s 50-day moving average is $7.09 and its 200 day moving average is $8.17. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market cap of $979.26 million, a P/E ratio of 12.05 and a beta of 1.85.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. Research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.